Australian Stem Cell Company Mesoblast To Get AU$170 Million Private Placement As Clinical Trials Ramp Up
This article was originally published in PharmAsia News
Executive Summary
Mesoblast Ltd., which Teva holds a 20% stake in, aims to raise AU$170 million by issuing new shares to a select group of existing and new global institutional investors.
You may also be interested in...
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.
Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology
Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.